In particular, lower levels and activity of PGC-1α (peroxisome proliferator–activated receptor-gamma co-activator 1 alpha) have been reported in cellular and animal models and in patients of ALS, PD, and HD.2, –4It is then not surprising that increasing mitochondrial function is being pursued as a promising therapeutic approach in these neurodegenerative disorders. Here, PPARGC1A is linked to Huntington disease.